Mind Medicine (MNMD) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Mind Medicine has commenced its Phase 3 Voyage study, dosing the first patient with MM120, an optimized form of LSD, for treating Generalized Anxiety Disorder (GAD). This study aims to assess the drug’s efficacy and safety compared to a placebo, building on promising Phase 2b results. The company plans to enroll approximately 200 participants in the U.S., with a second trial set to start in 2025 in the U.S. and Europe.
For further insights into MNMD stock, check out TipRanks’ Stock Analysis page.
